Pages that link to "Q70662768"
Jump to navigation
Jump to search
The following pages link to Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years (Q70662768):
Displaying 50 items.
- Subcutaneous apomorphine in Parkinson's disease (Q24524183) (← links)
- Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology (Q26738349) (← links)
- Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program (Q26800233) (← links)
- Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease (Q28215872) (← links)
- Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma? (Q28366409) (← links)
- Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study (Q30366253) (← links)
- Dopamine agonists (Q33545297) (← links)
- Novel drugs for Parkinson's disease (Q33545309) (← links)
- Treating and preventing levodopa-induced dyskinesias: current and future strategies (Q33688757) (← links)
- Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study (Q33734263) (← links)
- Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. (Q33747108) (← links)
- Emergency department presentations of patients with Parkinson's disease (Q33883388) (← links)
- Idiopathic Parkinson's disease: epidemiology, diagnosis and management. (Q34053847) (← links)
- Continuous dopamine-receptor stimulation in advanced Parkinson's disease (Q34070913) (← links)
- Postural instability in patients with Parkinson's disease. Epidemiology, pathophysiology and management (Q34306751) (← links)
- D1 dopamine receptors (Q34349190) (← links)
- Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. (Q35019451) (← links)
- Prevention and treatment of motor fluctuations (Q35198070) (← links)
- Apomorphine in idiopathic restless legs syndrome: an exploratory study (Q35486302) (← links)
- Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa (Q35614156) (← links)
- Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease (Q35868420) (← links)
- Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease (Q36318159) (← links)
- Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. (Q36319026) (← links)
- Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease. (Q36484966) (← links)
- When should levodopa therapy be initiated in patients with Parkinson's disease? (Q36791053) (← links)
- Drug treatment of Parkinson's disease (Q36902632) (← links)
- Current status of symptomatic medical therapy in Parkinson's disease (Q37131229) (← links)
- Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review (Q37302240) (← links)
- Dopamine receptor agonists in the treatment of advanced Parkinson's disease (Q37685684) (← links)
- What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? (Q37824279) (← links)
- The pharmacological properties and therapeutic use of apomorphine (Q38008194) (← links)
- Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease (Q38526848) (← links)
- Advanced stages of PD: interventional therapies and related patient-centered care (Q38542180) (← links)
- Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia. (Q38762256) (← links)
- Drug treatment of Parkinson's disease in the 1990s. Achievements and future possibilities (Q40906354) (← links)
- Pharmacokinetic optimisation in the treatment of Parkinson's disease (Q40937861) (← links)
- Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine (Q43144417) (← links)
- Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage (Q43568109) (← links)
- Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice. (Q43919475) (← links)
- Apomorphine in the treatment of Parkinson's Disease (Q45183861) (← links)
- Induction of tolerance of dopaminergic responses in man. (Q46572925) (← links)
- Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement (Q46798022) (← links)
- Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients (Q48236134) (← links)
- Are All Dopamine Agonists Essentially the Same? (Q64768956) (← links)
- Parkinson's disease. (Q67209950) (← links)
- Parkinson's disease (Q72250208) (← links)
- Dopamine D(2) activity of R-(-)-apomorphine and selected analogs: a microdialysis study (Q73349057) (← links)
- [Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease] (Q79210313) (← links)
- Dopamine receptor pharmacology (Q82029300) (← links)
- MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348 (Q86572676) (← links)